Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
409 - 420 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Safety and Immunogenicity of a Hantaan Virus DNA Vaccine and a Puumala Virus DNA Vaccine, For The Prevention of Hemorrhagic Fever With Renal Syndrome
Unknown
A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/16/2022
Locations: Clinical Trials Center, Walter Reed Army Institute of Reserach, Silver Spring, Maryland
Conditions: Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Novelty, Conformity and Trust in COVID-19 Vaccines
Completed
Despite their established benefits as public measures, vaccines continue to be treated with suspicion by many people, in the US and other parts of the world (Larson et al. 2014; Olive et al. 2018; Lazarus et al. 2020). Since the success of vaccines depends on their high uptake level (Anderson and May, 1985; Fine et al. 2011; Fontanet and Cauchemez, 2020), identifying factors that influence low trust and decision-making in relation to vaccines is essential in order to combat diseases such as the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2022
Locations: SurveyMonkey, San Mateo, California
Conditions: Trust
Umbilical Cord Blood Infusion to Treat Type 1 Diabetes
Completed
While this study is now completely enrolled, we do hope to develop a "next generation" cord blood based study sometime in early 2009. Please continue to contact us if you have a child with newly diagnosed Type 1 Diabetes (T1D) who alo has their OWN cord blood in storage.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/03/2022
Locations: University of Florida, Gainesville, Florida
Conditions: Type 1 Diabetes Mellitus
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
Completed
The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/25/2021
Locations: University Of Colorado, Aurora, Colorado +21 locations
Conditions: Advanced Cancer
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Birmingham VAMC, Birmingham, Alabama +189 locations
Conditions: Heart Failure, Myocardial Infarction
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
Completed
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria. The purpose of this dose escalation clinical study is to assess the safety, tolerability/reactogenicity, and immunogenicity of H3N2 M2SR investigational vaccines for prevention of influenza, when delivered at higher dosages or in two doses . Eligible subjects will be screened and randomized to receive two administrati... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/10/2021
Locations: RCA, Hollywood, Florida +3 locations
Conditions: Influenza A
A Safety and Immunogenicity Trial of IHV01
Completed
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
11/15/2021
Locations: University of Maryland, Institute of Human Virology, Baltimore, Maryland
Conditions: HIV Infection
Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Completed
This study will assess the safety, tolerability and immune response of 13-valent pneumococcal conjugate vaccine (13vPnC) compared with 23-valent Pneumococcal Polysaccharide Vaccine (23vPS). Although the study started with only 1 population, amendments to the original protocol will now reflect three participant populations. Three age cohorts will be enrolled. The first cohort (age 60-64) will be blinded. Cohort 2 (age 50-59) and cohort 3 (age 18-49) are open label. Subjects in cohorts 1 and 2 wil... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/11/2021
Locations: Accelovance, Huntsville, Alabama +25 locations
Conditions: Pneumococcal Infections
Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines
Completed
This is a prospective, single-site, randomized, then open-label study designed to develop a detailed transcriptional and epigenetic profile of the immune response to pneumococcal vaccination with conjugated and non-conjugated polysaccharide vaccines in the senescent immune system of older adults.
In this study, 40 healthy adults ages 60 and older that have never received pneumococcal vaccination, will be randomized in a 1:1 ratio to receive Prevnar-13 (Pfizer), a conjugated 13-valent vaccine or... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/08/2021
Locations: UConn Center On Aging, Farmington, Connecticut
Conditions: Pneumonia, Aging
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients
Completed
HIV vaccines may help the immune systems of HIV infected patients better control the virus. The goal of this study is to determine whether patients on anti-HIV medications can stop taking those medications if they receive an HIV vaccine. While taking anti-HIV medications, participants will receive either an HIV vaccine or a placebo. Participants will then stop taking their anti-HIV medications and the study will compare the viral loads of participants who received the vaccine with the viral load... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/04/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +27 locations
Conditions: HIV Infections
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Completed
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer. This study will evaluate the effectiveness of the Food and Drug Administration (FDA)-approved quadrivalent HPV vaccine, Gardasil, at preventing anal HPV infection in HIV-infected MSM and HIV-infected women.
Gender:
ALL
Ages:
27 years and above
Trial Updated:
10/29/2021
Locations: UCLA CARE Center CRS, Los Angeles, California +23 locations
Conditions: HIV Infections
Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs
Completed
The purpose of this study is to determine immune system function following vaccination in HIV-infected children currently taking anti-HIV drugs. To test the effectiveness of prior vaccination, patients in this study will receive booster shots of one of two pneumococcal vaccines, a hepatitis B vaccine, and a measles vaccine.
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
10/28/2021
Locations: UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama +25 locations
Conditions: HIV Infections
409 - 420 of 948